{
  "docId": "019de075-dd1e-7468-9323-d12fde1b7732",
  "docSlug": "a9cc0c508d45d8985f57408ace49b969",
  "documentTitle": "RayzeBio | IPO Presentation Deck | 41 slides",
  "authorId": "rayzebio",
  "authorName": "RayzeBio",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2023-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 21,
  "pageCount": 41,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide uses a standard clinical trial flow diagram (Population -> Treatment -> Endpoints -> Crossover).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/21",
  "deckHref": "/decks/019de075-dd1e-7468-9323-d12fde1b7732",
  "deckJsonHref": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json",
  "deckAnchorHref": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "diagram",
      "text": "Population, Treatment, Endpoints, Crossover",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0b94272c-db20-4e58-8458-84a451f686b2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.25,
        "x": 0.05,
        "y": 0.28
      },
      "kind": "list",
      "text": "Key Eligibility Criteria: Age >= 18, Histologically proven GEP-NETs, Ki-67 <= 20%, Progressive GEP-NET, Stable disease, RECIST v1.1 measurable, ECOG <= 2, CrCl >= 60 mL/min",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "38dbd1bd-2fed-4890-81b2-808b83fb824f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.2,
        "x": 0.75,
        "y": 0.75
      },
      "kind": "paragraph",
      "text": "Crossover to RYZ101 at PD (centrally confirmed)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "84e83a60-9ec8-4549-a44d-1128420cd36e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.2,
        "x": 0.75,
        "y": 0.3
      },
      "kind": "table",
      "text": "Statistical Assumptions: N=288, Mean HR=0.62, Power=90%, Critical HR interim=0.680, Critical HR final=0.751, Control arm=10 mo",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b30ee524-6e70-4c39-96a4-d2c6c95e8fd7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.35,
        "x": 0.15,
        "y": 0.05
      },
      "kind": "title",
      "text": "RYZ101 Phase 3 Trial Design",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "760b19f6-819c-44b1-92f6-c8895f69f9ac",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "1f1cde42-58e3-46d8-afbf-74acb80993c5",
      "evidence": "List of Key Eligibility Criteria",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "clinical-trial-design",
      "slug": null,
      "matchId": "0b1797e5-d20c-4c4d-befb-317fa0500738",
      "evidence": "Standardized flow of patient population to treatment arms and endpoints",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 21,
      "from": 16,
      "name": "Hypothesis Test",
      "slug": "42-hypothesis-test",
      "bestFor": "Strategy validation, due diligence, research presentations",
      "matchId": "dd065b7b-77b8-4f37-837e-80ec7e755de5",
      "evidence": "The document presents clinical trial results for RYZ101, including Phase 1b preliminary response analysis and efficacy data.",
      "position": 2,
      "objective": "How does RYZ101 perform in clinical trials?",
      "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)",
      "confidence": 0.7,
      "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}